Re­gen­eron hands off ex-US rights for cho­les­terol dis­or­der drug to rare dis­ease spe­cial­ist Ul­tragenyx

Re­gen­eron has held high hopes for evinacum­ab, a rare cho­les­terol dis­or­der drug that earned a first-in-class nod from the FDA ear­ly last year, as a cen­ter­piece of its car­diometa­bol­ic fran­chise. Now, the com­pa­ny is tap­ping an ul­tra-rare spe­cial­ist to take evinacum­ab to the next lev­el abroad.

Re­gen­eron will re­ceive $30 mil­lion in up­front cash and a po­ten­tial $63 mil­lion in down­stream mile­stones from Ul­tragenyx for ex-US li­cens­ing rights to Evkeeza (evinacum­ab), an ANGPTL3 block­er with an FDA ap­proval to treat a rare cho­les­terol dis­or­der along­side LDL-C low­er­ing ther­a­py and di­et, the com­pa­nies said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER